Leukemias, lymphomas, and other hematologic cancers:

Indications for IDAMYCIN PFS:

Acute myeloid leukemia, in combination with other antileukemic drugs.


Give by slow IV infusion (over 10–15mins). 12mg/m2 daily for 3 days (in combination with cytarabine). May give 2nd course if needed; if toxicity develops after 1st course, delay until resolved; reduce dose by 25%. Hepatic and renal impairment: consider reduce dose.


Not established.

Boxed Warning:

Extravasation. Myocardial toxicity. Severe myelosuppression. Hepatic or renal impairment.


Administer under the supervision of an experienced physician. Avoid in pre-existing bone marrow suppression. Increased risk of myocardial toxicity in pre-existing cardiovascular disease, previous anthracycline therapy at high cumulative doses, concomitant or previous mediastinal pericardial irradiation, anemia, bone marrow suppression, infections, leukemic pericarditis and/or myocarditis. Monitor CBCs, cardiac, hepatic and renal function prior to and during treatment. Monitor for hyperuricemia, infections. Hepatic or renal impairment (see Adults). Avoid extravasation. Elderly. Pregnancy: avoid. Nursing mothers: not recommended.

See Also:

Pharmacologic Class:



Concomitant drugs that suppress cardiac contractility or cardiotoxic drugs (eg, trastuzumab, cyclophosphamide, paclitaxel): not recommended; avoid use for at least 5 half-lives after discontinuing cardiotoxic drug (up to 7mos for trastuzumab).

Adverse Reactions:

Myelosuppression (may be severe), GI upset, mucositis, abdominal pain, alopecia, rash, inj site reactions, cardiotoxicity (eg, CHF, arrhythmias, chest pain, MI, asymptomatic declines in LVEF).

How Supplied:

Single-dose vials—contact supplier; PFS: Single-dose vials (5mL, 10mL, 20mL)—1